Our findings suggest that MSN facilitates the progression of colorectal cancer by activating the β-catenin–RUNX2 axis, highlighting the potential of MSN as a promising therapeutic target for treating CRC (Figure 10). The gene discussed is RUNX2; the disease is colorectal cancer.